RenovoRx, Inc. 8-K

What Happened
RenovoRx, Inc. (RNXT) filed an 8‑K reporting that Nasdaq notified the company it remains non‑compliant with the $1.00 minimum bid price required for continued listing under Nasdaq Listing Rule 5550(a)(2). The company previously received a deficiency notice on December 31, 2025 and was first given 180 days (until June 30, 2026) to regain compliance. On July 1, 2026 Nasdaq granted a second 180‑day compliance period under Rule 5810(c)(3)(A), extending the deadline to December 28, 2026.

Key Details

• Deficiency notice originally received: December 31, 2025 (failure to meet $1.00 minimum bid price).
• Initial compliance period: 180 days, ending June 30, 2026.
• Second compliance period granted: additional 180 days, ending December 28, 2026.
• To regain compliance Nasdaq requires a closing bid of at least $1.00 per share for a minimum of 10 consecutive business days; if not achieved by Dec 28, 2026 Nasdaq will notify the company of delisting (the company can appeal to a Hearings Panel).

Why It Matters
This filing is material for investors because continued failure to meet Nasdaq’s minimum bid price could lead to delisting of RNXT shares, which can reduce liquidity and limit where shares trade. The company now has a clear additional timeline (through December 28, 2026) to restore the stock price above $1.00 for the required period; investors should monitor the stock price and any company actions (such as share consolidations or corporate developments) aimed at regaining compliance.